Osteoarthritis Treatment and Pain Relief
Standard therapies, commonly used drugs and injections, and practical alternatives for a person in their 70s with painful legs or knees
Executive Summary
Osteoarthritis (OA) is not simply “worn cartilage.” Modern guidelines treat it as a whole-joint disease involving cartilage loss, subchondral bone change, osteophytes, synovial inflammation, pain sensitization, muscle weakness, and mechanical overload. The practical implication is important: the best care is usually not a single injection or painkiller. The standard approach is layered: diagnosis and risk stratification, exercise and weight management, topical pain relief, cautious oral medication, selected intra-articular injections, assistive devices, and timely referral for joint replacement when pain and disability remain severe despite conservative care.
For knee OA, the strongest recurring themes across the American College of Rheumatology/Arthritis Foundation (ACR/AF), NICE, and orthopedic guidance are therapeutic exercise, weight loss when overweight, self-management education, cane or brace use when mechanics require it, topical NSAIDs, oral NSAIDs when risks are acceptable, and intra-articular corticosteroid injection for short-term relief. Acetaminophen, duloxetine, topical capsaicin, acupuncture, radiofrequency ablation, and tramadol occupy more conditional or selected-use territory. Hyaluronic acid injections are widely used in Korea and some other markets, and Korea has reimbursed sodium hyaluronate products for knee OA under defined conditions; however, international guidelines are mixed because average trial effects are modest and product quality varies. Platelet-rich plasma (PRP), stem-cell products, exosomes, and many “regenerative” injections are popular private-pay options, but the evidentiary and regulatory quality is uneven. They should not be presented as proven cartilage-regrowth therapy for an elderly patient.
In a 70s patient already receiving joint injections and oral analgesics, the key clinical question is whether pain is mainly from knee OA, hip OA, lumbar spinal stenosis/radiculopathy, vascular claudication, neuropathy, or a combination. Many older patients describe “leg pain,” but knee joint injections will not solve pain that is driven primarily by spinal stenosis, peripheral artery disease, or neuropathy. A sensible next step is therefore not just another injection; it is a structured reassessment: pain location, walking distance, night pain, neurologic findings, plain radiographs if needed, kidney function, current medication list, and the prior response duration to injections.
Diagnosis and First Principles
NICE recommends that OA can often be diagnosed clinically without routine imaging in people aged 45 or older who have activity-related joint pain and either no morning stiffness or morning stiffness lasting no longer than 30 minutes. Imaging becomes more useful when symptoms are atypical, severe, rapidly progressive, traumatic, inflammatory, or when surgery is being considered. This matters because X-ray severity and pain do not always correlate. A patient may have severe X-ray OA with moderate pain, or severe pain with only moderate radiographic change due to synovitis, meniscal pathology, central sensitization, spine disease, or poor muscle support.
The most defensible treatment plan starts with function: walking distance, stair climbing, ability to stand from a chair, sleep disruption, falls, and use of analgesics. For an elderly patient, the treatment target is usually not “cartilage restoration” but fewer flares, safer walking, better sleep, preserved independence, and avoidance of medication harm. That framing prevents overreliance on expensive injections with weak proof and underinvestment in strength, balance, footwear, and assistive devices.
Knee/hip OA vs spine, nerve, vascular, gout, fracture, infection.
Strength, weight if relevant, cane, brace, footwear, pacing.
Topical NSAID, acetaminophen trial, cautious oral NSAID if appropriate.
Steroid flare injection, selected HA, selected RFA/PRP discussion.
Refer when pain and disability remain severe despite optimized care.
Evidence-Based Treatment Map
| Category | Main options | Guideline position | Practical use in a 70s patient |
|---|---|---|---|
| Exercise and physical therapy | Quadriceps/hip strengthening, aerobic walking or cycling, aquatic exercise, balance training | Strong/core in ACR/AF and NICE | Often the highest value intervention. Start low, supervised if possible, and expect mild early discomfort. Focus on strength and gait, not aggressive stretching alone. |
| Weight management | 5-10% body-weight reduction if overweight; diet plus low-impact activity | Strong/core when overweight or obese | Even modest weight loss reduces knee load; NICE notes 10% is likely better than 5%. Avoid frailty or sarcopenia from excessive dieting. |
| Assistive devices | Cane in opposite hand, tibiofemoral unloading brace, patellofemoral brace, shock-absorbing shoes | Strong/conditional depending on device and joint pattern | Underused in elderly patients. A cane can reduce knee load immediately and may prevent falls. Brace works best when OA compartment and alignment are identified. |
| Topical drugs | Topical diclofenac or other topical NSAID; capsaicin | Strong for topical NSAIDs in knee OA; capsaicin conditional | Usually preferred before oral NSAIDs in older adults because systemic exposure is lower. Watch skin irritation. |
| Oral drugs | Oral NSAIDs, acetaminophen, duloxetine, short-course tramadol in selected cases | NSAIDs strong but risk-limited; acetaminophen/duloxetine/tramadol conditional | Requires medication review. Kidney disease, hypertension, anticoagulants, heart failure, prior ulcer, and fall risk can change the choice. |
| Injections | Intra-articular corticosteroid; hyaluronic acid; PRP in selected private-pay settings | Steroid strongly recommended by ACR/AF for knee OA; HA mixed; PRP varies and is often not standard | Steroid is best for inflammatory flares and short-term relief. HA may be reasonable if prior benefit was durable. PRP requires careful discussion of cost and uncertainty. |
| Procedures and surgery | Radiofrequency ablation, joint replacement; avoid routine arthroscopy for degenerative OA | RFA conditional in ACR/AF; joint replacement appropriate for severe refractory disease; NICE discourages arthroscopy unless mechanical locking | Do not delay arthroplasty indefinitely if life-limiting pain persists and radiographic OA is advanced. Surgical risk should be assessed, not assumed from age alone. |
Medication and Injection Detail
| Treatment | Expected benefit | Key risks or limits | Insurance / Korea context |
|---|---|---|---|
| Topical NSAIDs diclofenac gel/patch and similar | Reduces localized knee or hand pain; useful for daily baseline pain. | Skin irritation; still use caution with very high-frequency application, but systemic risk is lower than oral NSAIDs. | Commonly used and practical. Particularly suitable as a first pharmacologic layer in older adults. |
| Oral NSAIDs celecoxib, naproxen, ibuprofen, aceclofenac etc. | Often stronger pain relief than acetaminophen; improves function during flares. | GI bleeding, kidney injury, hypertension, edema/heart failure, cardiovascular risk. Avoid or limit with anticoagulants, CKD, ulcer history, uncontrolled BP. | Covered when prescribed, but should be lowest effective dose and shortest necessary duration. Consider gastroprotection if GI risk is high. |
| Acetaminophen | May help mild pain; safer for stomach/kidney than NSAIDs at appropriate dose. | Average OA effect is small. Liver toxicity risk with excess dose, alcohol use, or liver disease. | Useful as adjunct, not enough alone for many moderate-to-severe knee OA patients. |
| Duloxetine | Can help chronic musculoskeletal pain, especially when pain sensitization, poor sleep, anxiety, or widespread pain coexist. | Nausea, dizziness, sleep change, blood pressure effects, drug interactions; taper rather than abrupt stop. | Recognized in international guidance as conditional. Consider if NSAIDs are risky or pain is centralized. |
| Tramadol / weak opioids | Short-term rescue when other options fail or while awaiting surgery. | Falls, confusion, constipation, nausea, dependence, interaction with antidepressants; higher concern in 70s patients. | Should be cautious and time-limited. Avoid as a chronic default plan. |
| Intra-articular corticosteroid | Good short-term relief for painful knee effusion/synovitis; effect often weeks, sometimes longer. | Transient glucose rise, infection risk, post-injection flare; repeated frequent injections raise concern for cartilage and systemic effects. | Widely used. Best when timed for flares, not as automatic monthly maintenance. |
| Hyaluronic acid injection | May improve pain in selected knee OA patients over weeks to months; less immediate than steroid. | Mixed evidence, product differences, local swelling/pain; less useful in very advanced bone-on-bone OA for many patients. | Korea has reimbursed sodium hyaluronate products for knee OA under benefit criteria; HIRA has also reviewed newer HA products. International guidelines are more skeptical than Korean practice patterns. |
| PRP | Some trials suggest pain/function improvement in mild-to-moderate knee OA, often compared with HA. | Protocol variability, platelet concentration differences, activation methods, cost, uncertain durability, weaker standardization. | Often non-covered/private-pay. Reasonable only after transparent discussion that it is not guaranteed cartilage regeneration. |
| Stem cell / exosome injections | Marketed as regenerative; high patient interest. | Evidence and regulation remain major issues; risk of misleading claims, infection, cost, and unproven structural benefit. | Should be treated cautiously. For an elderly patient, do not substitute this for proven pain control, function work, or surgical evaluation when severe. |
| Genicular nerve radiofrequency ablation | May reduce knee pain when surgery is not desired or is delayed; targets pain nerves rather than cartilage. | Not disease-modifying; benefit varies; requires diagnostic block and procedural expertise. | Often considered when medications are risky and injections are insufficient. Coverage varies by system and indication. |
Relative Strength of Practical Options
Core
Core
Strong
Risk-based
Short-term
Selected
Private-pay
Chart is a qualitative synthesis of guideline strength, safety, and practical value, not a head-to-head efficacy ranking.
What to Do When a 70s Patient Has Leg Pain Despite Injections and Painkillers
A patient in their 70s who says “my legs hurt” and is already taking analgesics plus receiving joint injections needs a broader differential diagnosis. Knee OA pain is commonly located around the joint line, worsens with stairs, squatting, standing, and walking, and may improve with rest. Hip OA can present as groin pain, lateral hip pain, buttock pain, or even referred knee pain. Lumbar spinal stenosis causes leg pain, heaviness, numbness, or weakness that worsens with walking or standing and improves when sitting or bending forward. Peripheral artery disease causes exertional calf or thigh pain relieved by rest. Neuropathy causes burning, tingling, or numbness. Treating all of these as “knee arthritis” leads to poor results.
The practical alternative plan should begin with reassessment rather than escalation. A clinician should review the pain map, walking tolerance, neurologic signs, vascular pulses, medication list, prior imaging, and response to each injection. If corticosteroid injection helped for only a few days, repeated steroid injections may not be worthwhile. If HA gave several months of relief and the patient has moderate OA rather than end-stage deformity, another course may be reasonable. If pain relief is poor despite technically correct knee injections, look for hip or spine disease.
Non-drug measures can be surprisingly powerful in this age group. A cane held in the opposite hand can reduce medial knee load immediately. A tibiofemoral unloading brace can help unicompartmental OA, especially varus medial-compartment disease, although comfort and compliance determine success. Supervised physical therapy should focus on quadriceps strength, hip abductor strength, sit-to-stand mechanics, balance, and gait training. Aquatic exercise is useful when land exercise hurts too much. Footwear should be stable; slippers and loose sandals increase fall risk. Home safety review matters because pain treatment that causes dizziness may solve one problem while creating a fracture risk.
For drug strategy, topical NSAID should usually be maximized first for knee/hand OA. Oral NSAID can be effective, but in a 70s patient it should not be casual. Check serum creatinine/eGFR, blood pressure, edema, heart failure, coronary disease, stroke history, ulcer history, anticoagulant or antiplatelet use, and concurrent steroids. If oral NSAID is used, it should be at the lowest effective dose, for limited periods, and with gastroprotection when appropriate. Acetaminophen may be used as an adjunct, but it should not be expected to control severe OA by itself. Duloxetine is worth discussing when pain is chronic, sleep is poor, NSAIDs are risky, or there is a sensitized pain pattern. Tramadol should be a fallback, time-limited option because falls, confusion, and constipation are material risks in older adults.
Injection choices should be matched to the clinical situation. Intra-articular steroid is most rational when there is a flare, swelling, or inflammatory pain. It is less compelling as routine maintenance every few weeks. HA injection is more controversial internationally, but it remains commonly used in Korea and may be reasonable when the patient previously responded, wants to avoid oral NSAID exposure, and understands that benefit is gradual and not guaranteed. PRP can be discussed if the patient is willing to pay and has mild-to-moderate OA, but expectations must be conservative. Stem-cell or exosome marketing should be viewed with skepticism unless delivered under a properly regulated clinical framework.
Finally, surgery should not be framed as failure. For severe radiographic knee or hip OA with persistent pain, night symptoms, loss of independence, and inadequate response to optimized conservative care, referral to an orthopedic surgeon for joint replacement evaluation is standard. Age alone is not a contraindication; frailty, cardiopulmonary risk, infection risk, diabetes control, bone quality, social support, and rehabilitation capacity matter more. Delaying surgery for years through repeated low-yield injections can sometimes worsen deconditioning and surgical recovery.
Korea-Specific Practical Notes
| Issue | Practical interpretation |
|---|---|
| Hyaluronic acid practice | HA injections are more embedded in Korean orthopedic practice than in some US/UK guideline positions. HIRA materials show sodium hyaluronate products reviewed for knee OA reimbursement. The important question is whether the individual patient had meaningful prior benefit and whether OA severity is suitable. |
| Non-covered therapies | PRP, some radiofrequency procedures, stem-cell/exosome-style injections, high-end braces, and some rehabilitation packages may be non-covered or variably covered. Non-coverage does not automatically mean useless, but it should trigger a higher burden of proof and clear cost-benefit discussion. |
| Older adult medication safety | Korean patients often receive combinations of analgesics, muscle relaxants, gastrointestinal drugs, supplements, and injections from multiple clinics. Medication reconciliation is essential to avoid duplicate NSAIDs, sedatives, and kidney-risk combinations. |
| When to seek specialist review | Progressive deformity, recurrent falls, severe walking limitation, night pain, inadequate injection response, suspected spinal stenosis, or unclear pain origin should prompt orthopedic, rehabilitation medicine, rheumatology, pain clinic, or spine evaluation depending on symptoms. |
Suggested Decision Framework for the Family
| Question to ask the doctor | Why it matters |
|---|---|
| Is the pain truly from knee OA, or could it be hip, lumbar spine, vascular, or nerve pain? | Different causes require different treatments; repeated knee injections will fail if the pain generator is elsewhere. |
| What is the X-ray grade and alignment pattern? | Moderate OA may justify conservative care and selected injections; end-stage bone-on-bone OA may require surgical discussion. |
| How long did the last steroid or HA injection help? | Duration of response is one of the best practical guides to whether repeating the same injection is rational. |
| Are kidney function, blood pressure, stomach bleeding risk, and heart risk acceptable for oral NSAIDs? | NSAIDs can be effective but are among the most important medication hazards in older adults. |
| Would a cane, brace, or supervised strengthening program reduce load enough to delay escalation? | Mechanical interventions can reduce pain without systemic side effects. |
| Is it time for joint replacement evaluation? | Consultation does not force surgery; it clarifies options, timing, and risk. |
Bottom Line
For an older patient with painful legs or knees, the best plan is a layered, diagnosis-aware strategy. Start by confirming the pain source. Use exercise, strength, weight management if relevant, cane/bracing, and topical NSAIDs as low-risk foundations. Use oral NSAIDs only after risk review. Use steroid injections for short-term inflammatory flares rather than indefinite routine treatment. Consider HA when prior response and Korean practice context support it, while recognizing mixed international evidence. Treat PRP and other non-covered interventions as optional, evidence-limited choices rather than standard care. If pain remains disabling despite well-executed conservative therapy, surgical evaluation is part of standard treatment, not a last-resort stigma.
References
- Kolasinski SL et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatology / Arthritis Care & Research. doi: 10.1002/art.41142 and 10.1002/acr.24131.
- NICE Guideline NG226. Osteoarthritis in over 16s: diagnosis and management. Recommendations on clinical diagnosis, exercise, weight management, pharmacologic therapy, follow-up, referral, and arthroscopy.
- American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Knee, Evidence-Based Clinical Practice Guideline, 3rd edition.
- CMS Local Coverage Determination materials on hyaluronic acid injections for knee osteoarthritis, summarizing rationale and coverage constraints in the US Medicare context.
- Health Insurance Review & Assessment Service (HIRA), Korea. Drug reimbursement review materials including sodium hyaluronate products for knee osteoarthritis.